Get your patient on Edex (Alprostadil)
Edex patient education
Patient toolkit
Dosage & administration
Edex prescribing information
INDICATIONS AND USAGE
edex ® is indicated for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.
DOSAGE AND ADMINISTRATION
edex ® in the Treatment of Erectile Dysfunction
The dosage range of edex ® for the treatment of erectile dysfunction is 1 to 40 mcg. The intracavernous injection should be given over a 5 to 10 second interval. In a study with a dose range of 1 to 20 mcg of edex ® , the mean dose was 10.7 mcg at the end of the dose titration period. In two studies with a dose range of 1 to 40 mcg of edex ® , the mean dose was 21.9 mcg at the end of the dose titration period. Doses greater than 40 mcg have not been studied. A ½-inch, 27- to 30-gauge needle is generally recommended for the intracavernous injection. The patient is advised not to exceed the optimum edex ® dose which was determined in the doctor's office. The lowest possible effective dose should always be used.
Initial Titration in Physician's Office
Erectile Dysfunction of Vasculogenic, Psychogenic, or Mixed Etiology :
Dosage titration should be initiated at 2.5 mcg of alprostadil. If there is a partial response, the dose may be increased by 2.5 mcg to a dose of 5 mcg and then in increments of 5 to 10 mcg, depending upon erectile response, until the dose that produces an erection suitable for intercourse and not exceeding a duration of 1 hour is reached. If there is no response to the initial 2.5-mcg dose, the second dose may be increased to 7.5 mcg, followed by increments of 5 to 10 mcg. The patient must stay in the physician's office until complete detumescence occurs. If there is no response, then the next higher dose may be given within 1 hour. If there is a response, then there should be at least a 1-day interval before the next dose is given.
Erectile Dysfunction of Pure Neurogenic Etiology (Spinal Cord Injury):
Dosage titration should be initiated at 1.25 mcg of alprostadil. The dose may be increased by 1.25 mcg to a dose of 2.5 mcg, followed by an increment of 2.5 mcg to a dose of 5 mcg, and then in 5-mcg increments until the dose that produces an erection suitable for intercourse and not exceeding a duration of 1 hour is reached. The patient must stay in the physician's office until complete detumescence occurs. If there is no response, then the next higher dose may be given within 1 hour. If there is a response, then there should be at least a 1-day interval before the next dose is given.
At-Home (Maintenance Therapy) Dosing Instructions
The first injections of edex ® must be done at the physician's office by medically trained personnel. Self-injection therapy by the patient can be started only after the patient is properly instructed and well trained in the self-injection technique. The physician should instruct the patient to discard any needles which become bent during the self-injection procedure as these needles may break. The physician should make a careful assessment of the patient's skills and competence with the self-injection procedure. The intracavernous injection must be done under sterile conditions. The site of injection is usually along the lateral aspect of the proximal third of the penis. Visible veins should be avoided. The side of the penis that is injected and the site of injection must be alternated. The injection site must be cleansed with an alcohol swab before injection.
The dose of edex ® that is selected for self-injection treatment should provide the patient with an erection that is satisfactory for sexual intercourse and that is maintained for no longer than 1 hour. If the duration of erection is longer than 1 hour, the dose of edex ® should be reduced. The lowest effective dose should be used at home. Self-injection therapy for use at home should be initiated at the dose that was determined in the physician's office. Dose adjustment may be required and should be made only after consultation with the physician.
Careful and continuous follow-up of the patient while in the self-injection program must be exercised. This is especially true for the initial self-injections, since adjustments in the dose of edex ® may be needed. The recommended frequency of injection is no more than 3 times weekly, with at least 24 hours between each dose. The reconstituted edex ® cartridge and needle are intended for single use only and should be discarded after use. The user should be instructed in the proper disposal of the needles and cartridges.
While on self-injection treatment, it is recommended that the patient visit the prescribing physician's office every 3 months. At that time, the efficacy and safety of the therapy should be assessed, and the dose of edex ® should be adjusted, if needed.
The patient is instructed to follow the enclosed patient information pamphlet.
Preparation of Solution
The edex ® injection device is used to reconstitute the single-dose, dual-chamber cartridge. The plunger is used to force the sterile 0.9% sodium chloride (1.075 mL) in one chamber into the chamber containing alprostadil. After reconstitution, the edex ® injection device is used to administer the intracavernous injection of alprostadil. The reusable edex ® injection device is for use only with the cartridges and needles included in the edex ® Cartridge Packs.
Prepare the edex ® solution immediately before use. Do not administer unless solution is clear. Do not add any drugs or solutions to the edex ® solution. Discard any unused solution remaining in the cartridge. The reconstituted solution should not be stored.
The edex ® cartridge contains a solid layer or lyophilized cake of dry white powder approximately 3/8" in thickness. A normal cake may appear cracked or crumbled. If the cartridge is damaged, the cake may shrink in size. Do not use the cartridge if it appears damaged or the cake is substantially reduced in size.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. The reconstituted solution may initially appear cloudy due to small air bubbles. Do not use the solution if it remains cloudy, contains precipitates, or is discolored.
CAUTION: Do not reuse any solution remaining in the cartridge due to the possibility of bacterial contamination.
Administration
edex ® is given as an intracavernous injection over a 5- to 10-second interval. See patient information for edex ® .
Stability
The single-dose, dual-chamber cartridge should be reconstituted only when it is certain that the patient is ready to administer the drug. The reconstituted drug solution should be used immediately after reconstitution. Any solution remaining in the cartridge should be discarded.
CONTRAINDICATIONS
edex ® should not be used:
- in men who have conditions that predispose them to priapism, such as sickle cell anemia or sickle cell trait, multiple myeloma, or leukemia (see WARNINGS ) .
- for the treatment of erectile dysfunction in men with fibrotic conditions of the penis, such as cavernosal fibrosis or Peyronie’s disease (see PRECAUTIONS ) .
- in men with penile implants
ADVERSE REACTIONS
edex ® , administered by intracavernous injection in doses ranging from 1 to 40 mcg per injection for periods up to 24 months, has been evaluated in clinical trials for safety in over 1,065 patients with erectile dysfunction. Discontinuation of therapy due to a side effect in clinical trials was required in approximately 9% of patients treated with edex ® and in <1% of patients treated with placebo.
Local Adverse Reactions
The following local adverse reactions were reported in studies including 1,065 patients treated with edex ® for up to two years.
Penile Pain
With use of up to 24 months, penile pain was reported at least once by 29% of patients during injection, 35% of patients during erection, and by 30% of patients after erection. On a per injection basis, 15% of injections were associated with penile pain. Penile pain was judged by patients to be mild in intensity for 80% of painful injections, moderate in intensity for 16% of painful injections, and severe in intensity for 4% of painful injections. The frequency of penile pain reports decreased over time; 41% of the patients experienced pain during the first 2 months and 3% of the patients experienced pain during months 21 to 24. In placebo-controlled studies, penile pain was reported by 31% of patients after edex ® and by 9% of patients after placebo injection.
Prolonged Erection/Priapism
Prolonged erections greater than four hours in duration occurred in 4% of all patients treated up to 24 months. In placebo-controlled studies, 3% of patients treated with edex ® and <1% of patients treated with placebo reported prolonged erections greater than four hours. The incidence of priapism (erections greater than 6 hours in duration) was <1% with long-term use for up to 24 months. In the majority of cases, spontaneous detumescence occurred. A higher incidence of prolonged erections was found in younger patients (<40 years), non-diabetic patients, and patients with psychogenic etiology of erectile dysfunction ( See WARNINGS ).
Hematoma/Ecchymosis
In patients treated with edex ® for up to 24 months, local bleeding, hematoma, and ecchymosis were observed in 15%, 5%, and 4% of patients, respectively. In placebo-controlled studies, the frequency of local bleeding was 6% with injection of edex ® and 3% with injection of placebo. In most cases, these reactions were attributed to faulty injection technique.
| Local Adverse Reactions Reported by ≥1% of Patients | |||
|---|---|---|---|
| All Study Periods 1 | |||
| Local Reaction | edex® | Local Reaction | edex® |
| N = 1065 | N = 1065 | ||
| n (%) | n (%) | ||
| Penile pain during injection | 305 (29) | Ecchymosis | 44 (4) |
| Penile pain during erection | 368 (35) | Penile angulation | 72 (7) |
| Penile pain after erection | 317 (30) | Penile fibrosis | 52 (5) |
| Penile pain (other) 2 | 116 (11) | Cavernous body fibrosis | 20 (2) |
| Prolonged erection | Peyronie's disease | 11 (1) | |
| > 4 ≤ 6 Hours | 44 (4) | Faulty injection technique 3 | 59 (6) |
| > 6 Hours | 6 (<1) | Penis disorder | 28 (3) |
| Bleeding | 158 (15) | Erythema | 17 (2) |
| Hematoma | 56 (5) | ||
1 Protocol Numbers KU-620-001, KU-620-002, KU-620-003, F-8653. 2 Penile pain reported without an association to injection site or erection, such as pain in penis and scrotum, pain in glans penis, and burning penile pain. 3 Examples include injection into glans penis, urethra or subcutaneously. | |||
Systemic Adverse Experiences
The following systemic adverse experiences were reported in controlled and uncontrolled studies in ≥1% of patients treated for up to 24 months with edex ® .
| BODY SYSTEM | edex ® | BODY SYSTEM | edex ® | BODY SYSTEM | edex ® |
|---|---|---|---|---|---|
| Adverse Experience | N = 1065 | Adverse Experience | N = 1065 | Adverse Experience | N = 1065 |
| n (%) | n (%) | n (%) | |||
| RESPIRATORY | CARDIOVASCULAR | UROGENITAL | |||
| Upper respiratory tract | Hypertension | 17 (2) | Prostate disorder | 15 (1) | |
| infection | 58 (5) | Myocardial infarction | 13 (1) | Testicular pain | 13 (1) |
| Sinusitis | 14 (1) | Abnormal ECG | 12 (1) | Inguinal hernia | 11 (1) |
| BODY AS A WHOLE | |||||
| Influenza-like symptoms | 35 (3) | METABOLIC/NUTRITIONAL | DERMATOLOGIC | ||
| Headache | 20 (2) | Hypertriglyceridemia | 17 (2) | Skin disorder | 14 (1) |
| Infection | 18 (2) | Hypercholesterolemia | 12 (1) | SPECIAL SENSES | |
| Pain | 16 (2) | Hyperglycemia | 12 (1) | Abnormal vision | 11 (1) |
| MUSCULOSKELETAL | |||||
| Back pain | 23 (2) | ||||
| Leg pain | 13 (1) | ||||
| 1 Protocol Numbers KU-620-001, KU-620-002, KU-620-003, F-8653. | |||||
Hemodynamic changes, manifested as increases or decreases in blood pressure and pulse rate, were observed during clinical studies but did not appear to be dose-dependent. Four patients (<1%) reported clinical symptoms of hypotension such as dizziness or syncope.
edex ® had no clinically important effect on serum or urine laboratory tests.
Post-Marketing Adverse Experiences
Needle breakage.
Drug Interactions
The pharmacodynamic interaction between heparin (5,000 units) and alprostadil intravenous infusion (90 mcg over 3 hours) was investigated. The results indicate significant changes in partial thromboplastin time (140% increase) and thrombin time (120% increase). Therefore, caution should be exercised with concomitant administration of heparin and edex ® .
(Also, see Drug-Drug Interactions in CLINICAL PHARMACOLOGY, Pharmacokinetics .)
DESCRIPTION
edex ® (alprostadil for injection) is a sterile, pyrogen-free powder containing alprostadil in an alfadex (α-cyclodextrin) inclusion complex. Alprostadil is an endogenous substance known as prostaglandin E 1 (PGE 1 ). edex ® is supplied in single-dose, dual-chamber cartridges.
edex ® is lyophilized in single-dose, dual-chamber cartridges intended for use with the reusable edex ® injection device. One chamber of the cartridge contains alprostadil, alfadex and lactose as a sterile, pyrogen-free powder. The other chamber contains 1.075 mL of sterile 0.9% sodium chloride. The edex ® cartridges are supplied in three strengths: 10-mcg cartridge (10.75 mcg alprostadil, 347.55 mcg α-cyclodextrin, 51.06 mg lactose); 20-mcg cartridge (21.5 mcg alprostadil, 695.2 mcg α-cyclodextrin, 51.06 mg lactose); 40-mcg cartridge (43 mcg alprostadil, 1,390.3 mcg α-cyclodextrin, 51.06 mg lactose). The edex ® injection device is used to reconstitute the sterile powder in one chamber with the sterile 0.9% sodium chloride in the other chamber. After reconstitution, the edex ® injection device is used to administer the intracavernous injection of alprostadil.
The chemical name for alprostadil is (1R,2R,3R)-3-Hydroxy-2-[(E)-(3S)-3-hydroxy-1-octenyl]-5-oxocyclopentane heptanoic acid. The empirical formula is C 20 H 34 O 5 and the molecular weight is 354.49. The chemical structure is:
The α-cyclodextrin inclusion complex improves the water solubility of alprostadil. The empirical formula of α-cyclodextrin is C 36 H 60 O 30 and the molecular weight is 972.85.
The chemical structure is:
Alprostadil alfadex is a white, odorless, hygroscopic powder. It is freely soluble in water and practically insoluble in ethanol, ethyl acetate and ether. After reconstitution, the active ingredient, alprostadil, immediately dissociates from the α-cyclodextrin inclusion complex. The reconstituted solution is clear and colorless and has a pH between 4.0 and 8.0. When the single-dose, dual-chamber cartridge containing either 10.75, 21.5, or 43 mcg of alprostadil is placed into the edex ® injection device and reconstituted, the deliverable amount of alprostadil in each milliliter is 10, 20 or 40 mcg, respectively.
CLINICAL PHARMACOLOGY
Alprostadil (PGE 1 ) is one of the prostaglandins, a family of naturally occurring acidic lipids with various pharmacological effects. Endogenous PGE 1 is derived from dihomo-gamma-linolenic acid, a fatty acid found within the phospholipids of cellular membranes. As an endogenous substance, PGE 1 exerts its biological effects either directly or indirectly by regulating and modifying the synthesis and effects of other hormones and mediators.
Mode of Action
Alprostadil is a smooth muscle relaxant. Precontracted isolated preparations of the human corpus cavernosum, corpus spongiosum and cavernous artery are relaxed by alprostadil. Alprostadil has been shown to bind to specific receptors in human penile tissue. Two types of receptors that differ in their PGE 1 binding affinity have been identified. The binding of alprostadil to its receptors is accompanied by an increase in intracellular cAMP levels. Human cavernous smooth muscle cells respond to alprostadil by releasing intracellular calcium into the surrounding medium. Smooth muscle relaxation is associated with a reduction of the cytoplasmic free calcium concentration. Alprostadil also attenuates presynaptic noradrenaline release in the corpus cavernosum which is essential for the maintenance of a flaccid and non-erect penis.
Alprostadil induces erection by relaxation of trabecular smooth muscle and by dilation of cavernous arteries. This leads to expansion of lacunar spaces and entrapment of blood by compressing the venules against the tunica albuginea, a process referred to as the corporal veno-occlusive mechanism.
Pharmacokinetics
Alpha-Cyclodextrin
After reconstitution, PGE 1 immediately dissociates from the α-cyclodextrin inclusion complex; the in vivo disposition of both components occurs independently after administration. After intravenous infusion of radiolabeled α-cyclodextrin to healthy volunteers, the radiolabeled components were rapidly eliminated within 24-hours, urine accounting for 81% to 83% of radioactivity and feces for 0.1%. There was no evidence of significant accumulation of radiolabeled α-cyclodextrin in the body even after 7 days of repeated intravenous injection. After intracavernous administration in monkeys, radiolabeled α-cyclodextrin was rapidly distributed from the injection site with less than 0.1% of the dose remaining in the penis 1 hour after administration. There was no evidence of tissue retention of radiolabeled α-cyclodextrin in monkeys.
Alprostadil
Absorption
After intracavernous injection of 20 mcg of edex ® in 24 patients with erectile dysfunction, mean systemic plasma concentrations of PGE 1 increased from baseline of 0.8 ± 0.6 pg/mL to a peak (C max ) of 16.8 ± 18.9 pg/mL (corrected for baseline) within 2 to 5 minutes and dropped to endogenous plasma levels within 2 hours (Table 1). The absolute bioavailability of alprostadil estimated from systemic exposure was about 98% as compared to the same dose given by a short-term intravenous infusion.
Distribution
The volume of distribution for PGE 1 was not estimated. Approximately 93% of PGE 1 found in plasma is protein-bound.
Metabolism
PGE 1 is metabolized in the corpus cavernosum after intracavernous administration. PGE 1 entering the systemic circulation is rapidly and extensively metabolized in the lungs with a first-pass pulmonary elimination of 60 to 90% of PGE 1 . Enzymatic oxidation of the C15-hydroxy group followed by reduction of the C13, 14-double bond produces the primary metabolites, 15-keto-PGE 1 , 15-keto-PGE 0 , and PGE 0 . 15-keto-PGE 1 has only been detected in vitro in homogenized lung preparations, whereas 15-keto-PGE 0 and PGE 0 have been measured in plasma. Unlike the 15-keto metabolites which are less pharmacologically active than the parent compound, PGE 0 is similar in potency to PGE 1 in vitro using isolated animal organs.
After intracavernous injection of 20 mcg of edex ® to 24 patients with erectile dysfunction, mean systemic plasma 15-keto-PGE 0 levels increased within 7 minutes from endogenous levels of 12.9 ± 11.8 pg/mL to a C max of 421 ± 337 pg/mL (corrected for baseline) followed by a decrease to baseline levels in several hours. Mean systemic plasma PGE 0 levels increased within 20 minutes from endogenous levels of 0.6 ± 0.5 pg/mL to a C max of 3.9 ± 2.3 pg/mL (corrected for baseline) followed by a decrease to baseline levels in several hours.
Excretion
After further degradation of PGE 1 by beta and omega oxidation, the main metabolites are excreted primarily in urine (88%) and feces (12%) over 72 hours, and total excretion is essentially complete (92%) within 24 hours after administration. No unchanged PGE 1 has been found in the urine and there is no evidence of tissue retention of PGE 1 and its metabolites. After intracavernous injection of 20 mcg of edex ® in patients with erectile dysfunction, the terminal half-lives (t ½ ) of 15-keto-PGE 0 and PGE 0 were calculated to be 40.9 ± 16.5 minutes and 63.2 ± 31.1 minutes, respectively. The terminal half-life of PGE 1 in healthy volunteers was calculated to be around 9 to 11 minutes which is consistent with that reported in the literature (8 minutes).
Mean total body clearance of PGE 1 in patients with erectile dysfunction was calculated to be around 115 L/min after an intravenous infusion of 20 mcg alprostadil. The above value exceeded cardiac output indicating extensive and rapid elimination of PGE 1 in the lungs and/or blood.
Special Populations
Geriatric: The potential effect of age on the pharmacokinetics of alprostadil has not been formally evaluated.
Race: The potential influence of race on the pharmacokinetics of alprostadil has not been formally evaluated.
Hepatic Insufficiency
In a study in symptomatic subjects with impaired hepatic function and age/weight/sex-matched healthy volunteers, 120 mcg of alprostadil was administered by intravenous infusion over 2 hours. The mean C max value of PGE 1 in hepatically impaired patients was 96% higher than in healthy volunteers. Mean C max values of both 15-keto-PGE 0 and PGE 0 increased 65% as compared to those in healthy volunteers. The terminal half-lives of PGE 1 , PGE 0 , and 15-keto-PGE 0 and plasma albumin levels were similar in patients compared to healthy volunteers. Due to the fact that PGE 1 is primarily metabolized in the lung, the observed differences between hepatically impaired subjects and healthy volunteers were not anticipated; the mechanism responsible for the observed discrepancies is not known.
Renal Impairment
In a study in symptomatic subjects with end-stage renal disease undergoing hemodialysis and age/weight/sex-matched healthy volunteers, 120 mcg of alprostadil was administered by intravenous infusion over 2 hours. The mean C max value of PGE 1 in renally impaired patients was 37% lower as compared to that in healthy volunteers whereas mean C max values of 15-keto-PGE 0 and PGE 0 in these patients increased 104% and 145%, respectively, as compared to those in healthy volunteers. The terminal half-lives of PGE 1 , PGE 0, and 15-keto-PGE 0 and plasma albumin levels were similar in these patients vs healthy volunteers. The mechanism responsible for the observed discrepancies between renally impaired subjects and healthy volunteers is not known.
Pulmonary Disease
The pulmonary extraction of alprostadil following intravascular administration was reduced by 15% (66 ± 3.6% vs 78 ± 2.3%) in patients with acute respiratory distress syndrome (ARDS) compared with a group of patients with normal respiratory function who were undergoing cardiopulmonary bypass surgery. Pulmonary clearance was found to vary as a function of cardiac output and pulmonary intrinsic clearance in a group of 14 patients with ARDS or at risk of developing ARDS following trauma or sepsis. In this study, the pulmonary extraction efficiency of alprostadil ranged from subnormal (11%) to normal (90%), with an overall mean of 67%.
Drug-Drug Interactions
In clinical trials, concomitant use of agents such as antihypertensive drugs, diuretics, antidiabetic agents (including insulin), or nonsteroidal anti-inflammatory drugs had no apparent effect on the efficacy or safety of edex ® .
Aspirin, Warfarin, Digoxin, Glyburide
Several drug-drug interaction studies have been conducted with alprostadil alone or in combination with aspirin, digoxin or warfarin in healthy volunteers and with glyburide in subjects with stable, non-insulin dependent diabetes mellitus. The pharmacokinetic profiles of aspirin, warfarin, digoxin, and glyburide were not affected by concomitant administration of alprostadil. There were no clinically important changes or trends in pharmacodynamic parameters for these drugs.
Heparin
The pharmacokinetic and pharmacodynamic interaction between alprostadil intravenous infusion, 90 mcg over 3 hours, and heparin (5,000 IU) was evaluated in 12 healthy volunteers. Alprostadil had a significant effect on the pharmacodynamics of heparin resulting in a 140% increase in partial thromboplastin time and a 120% increase in thrombin time. Therefore, caution should be exercised with concomitant administration of heparin and edex ® .
| Table 1 | ||||||||
|---|---|---|---|---|---|---|---|---|
| Study No. | Participants | Route and Dose Administration | Drug/ Metabolites | C max 1 (pg/mL) | T max (min) | AUC 2 (pg∙min/mL) | Total Clearance 3 (L/min) | t 1/2 4 (min) |
| PHAKI 848 | Erectile Dysfunction Patients | 20 mcg/0.5 hr IV | PGE 1 | 7.09 ± 3.12 | 25.5 ± 4.8 | 174 ± 101 | 115 | --- |
| 15-keto- PGE 0 | 471 ± 88 | 30.0 ± 1.2 | 13705 ± 2559 | --- | 15.6 ± 5.6 | |||
| PGE 0 | 7.10 ± 2.19 | 32.2 ± 2.4 | 380 ± 115 | --- | 39.8 ± 26.3 | |||
| 20 mcg/IC | PGE 1 | 16.8 ± 18.9 | 4.8 ± 3.3 | 173 ± 115 | --- | --- | ||
| 15-keto- PGE 0 | 421 ± 337 | 9.7 ± 7.7 | 10500 ± 4101 | --- | 40.9 ± 16.5 | |||
| PGE 0 | 3.9 ± 2.3 | 20.3 ± 12.6 | 252 ± 134 | --- | 63.2 ± 31.1 | |||
1 Baseline-corrected data. 2 AUC 0-150 for intravenous (IV) infusion and AUC 0-120 for intracavernous (IC) injection. 3 Calculated as IV dose/AUC 0-150 (IV). 4 Apparent terminal half-life | ||||||||
Clinical Studies
In two studies (protocol numbers KU-620-001 [Study 1] and KU-620-002 [Study 2]), the safety and efficacy of edex ® were evaluated in 347 men with a diagnosis of erectile dysfunction due to vasculogenic, neurogenic and/or mixed etiology. Each study consisted of three phases: an in-office dose-titration phase, a two-week double-blind cross-over phase at home, and an open-label at home treatment phase that lasted for 12 months (Study 1) or six months (Study 2).
During the dose-titration phase, individualized optimum doses of edex ® were established. Erectile response was measured by the Buckling Test to assess axial penile rigidity. A positive Buckling Test was achieved if the erect penis was able to support an axial load of 1.0 kg without buckling of the penile shaft. During the subsequent two-week double-blind, cross-over phase, patients self-injected edex ® or placebo at home. Thereafter, patients continued to perform self-injections of open-label edex ® for six or 12 months, and the occurrence of an erection sufficient for sexual intercourse was documented following each injection.
Results
Study 1: One hundred fourteen men with a mean age of 53 years (range 22 to 65 years) were enrolled in the first phase. The mean optimum dose was 13.8 mcg (range 1 to 20 mcg). Seventy-six percent (87/114) of patients had an erection with a positive penile Buckling Test. Among the 71% (81/114) of patients who entered the placebo-controlled phase, an erection sufficient for sexual intercourse was achieved in 74% (60/81) of patients following edex ® injection compared to 7% (6/81) of patients following placebo injection. The mean duration of erection following edex ® was 56.9 minutes compared to 4.0 minutes following placebo. Among the 65% (74/114) of patients who entered the open-label treatment phase, the mean rate of response with an erection sufficient for sexual intercourse was 88.9% through 12 months. The average dose of edex ® remained essentially unchanged throughout the study duration.
Study 2: Two hundred thirty-three men with a mean age of 59.8 years (range 23 to 74 years) were enrolled in the first phase. The mean optimum dose was 25.9 mcg (range 1 to 40 mcg). Seventy-three percent (171/233) of patients had an erection with a positive penile Buckling Test. Among the 60% (141/233) of patients who entered the placebo-controlled phase, an erection sufficient for sexual intercourse was achieved in 73% (103/141) of patients following edex ® injection compared to 13% (18/141) of patients following placebo injection. The mean duration of erection following edex ® was 59.0 minutes compared to 7.6 minutes following placebo. Among the 60% (139/233) of patients who entered the open-label treatment phase, the mean rate of response with an erection sufficient for intercourse was 85.3% through six months. The average dose of edex ® remained essentially unchanged throughout the study duration.
Clinical Studies
In two studies (protocol numbers KU-620-001 [Study 1] and KU-620-002 [Study 2]), the safety and efficacy of edex ® were evaluated in 347 men with a diagnosis of erectile dysfunction due to vasculogenic, neurogenic and/or mixed etiology. Each study consisted of three phases: an in-office dose-titration phase, a two-week double-blind cross-over phase at home, and an open-label at home treatment phase that lasted for 12 months (Study 1) or six months (Study 2).
During the dose-titration phase, individualized optimum doses of edex ® were established. Erectile response was measured by the Buckling Test to assess axial penile rigidity. A positive Buckling Test was achieved if the erect penis was able to support an axial load of 1.0 kg without buckling of the penile shaft. During the subsequent two-week double-blind, cross-over phase, patients self-injected edex ® or placebo at home. Thereafter, patients continued to perform self-injections of open-label edex ® for six or 12 months, and the occurrence of an erection sufficient for sexual intercourse was documented following each injection.
HOW SUPPLIED
edex ® (alprostadil for injection) is available in single-dose, dual-chamber cartridges intended for use with the reusable edex ® injection device. One chamber of the cartridge contains 10.75, 21.5, or 43 mcg of alprostadil as a white, sterile, lyophilized powder. The other chamber contains 1.075 mL of sterile 0.9% sodium chloride. When the cartridge is placed into the edex ® injection device and reconstituted, the deliverable amount of alprostadil in each milliliter is 10, 20, or 40 mcg, respectively. edex ® Cartridge 2 Pack contains one reusable edex ® injection device, two single-dose, dual-chamber cartridges, two ½-inch, 29-gauge (0.33 mm × 12.7 mm) needles, and four alcohol swabs. edex ® Cartridge 6 Pack contains one reusable edex ® injection device, six single-dose, dual-chamber cartridges, six ½-inch, 29-gauge (0.33 mm × 12.7 mm) needles, and twelve alcohol swabs.
The edex ® cartridges are supplied in the following packages:
| edex ® Cartridge 2 Pack (includes one injection device, two cartridges, two needles and four alcohol swabs) | ||
| 10 mcg | 1 × 2 Pack | NDC 52244-010-02 |
| 20 mcg | 1 × 2 Pack | NDC 52244-020-02 |
| 40 mcg | 1 × 2 Pack | NDC 52244-040-02 |
| edex ® Cartridge 6 Pack (includes one injection device, six cartridges, six needles and twelve alcohol swabs) | ||
| 10 mcg | 1 × 6 Pack | NDC 52244-010-06 |
| 20 mcg | 1 × 6 Pack | NDC 52244-020-06 |
| 40 mcg | 1 × 6 Pack | NDC 52244-040-06 |
Store at 25°C (77°F); excursions permitted between 15°C - 30°C (59°F - 86°F).
Mode of Action
Alprostadil is a smooth muscle relaxant. Precontracted isolated preparations of the human corpus cavernosum, corpus spongiosum and cavernous artery are relaxed by alprostadil. Alprostadil has been shown to bind to specific receptors in human penile tissue. Two types of receptors that differ in their PGE 1 binding affinity have been identified. The binding of alprostadil to its receptors is accompanied by an increase in intracellular cAMP levels. Human cavernous smooth muscle cells respond to alprostadil by releasing intracellular calcium into the surrounding medium. Smooth muscle relaxation is associated with a reduction of the cytoplasmic free calcium concentration. Alprostadil also attenuates presynaptic noradrenaline release in the corpus cavernosum which is essential for the maintenance of a flaccid and non-erect penis.
Alprostadil induces erection by relaxation of trabecular smooth muscle and by dilation of cavernous arteries. This leads to expansion of lacunar spaces and entrapment of blood by compressing the venules against the tunica albuginea, a process referred to as the corporal veno-occlusive mechanism.
